By Monica Heger
Bio-Reference Laboratories' subsidiary GeneDx plans to launch sequencing-based prenatal tests by the end of this year, the company said last week in a conference call to discuss its second-quarter earnings.
"Our goal this year is to build out an unmatched one-stop shop for the entire spectrum of prenatal test offerings, from a more comprehensive approach for understanding the carrier status of expectant parents to advanced sequencing tests that will be recommended after abnormalities are seen on sonograms or on other genomic studies," Bio-Reference's CEO Marc Grodman said on the call.
Grodman said that the company has just started to offer these services through GeneDx, and expects a "full rollout" by the end of the year, although he did not provide details on the exact services.
He added that these types of efforts, while costly, are contributing to the company's growth, including a 23 percent increase in the number of patients serviced in the second quarter compared to the comparable period a year ago, as well as a 25 percent increase in revenue over last year's second quarter, to $137.7 million.
GeneDx currently offers a range of sequencing-based genetic tests on the Illumina Genome Analyzer in cardiology and mitochondrial disease, including for hypertrophic cardiomyopathy, long QT syndrome, and dilated cardiomyopathy.
Have topics you'd like to see covered by Clinical Sequencing News? Contact the editor at mheger [at] genomeweb [.] com.